The U.S. Food and Drug Administration has granted 510(k) clearance to Nephros Inc. for its EndoPur Endotoxin 10” Filter.

The filter fits into existing filter cartridge housings of the reverse osmosis water systems that provide dialysis clinics with high volumes of ultrapure water. The EndoPur offers dialysis clinics an endotoxin barrier with the smallest pore size on the market, according to Nephros.

“With the FDA clearance of the EndoPur, we have achieved a significant milestone in the expansion of our dialysis water filter portfolio,” said Daron Evans, president and CEO of Nephros.

Nephros said they expect to begin selling the EndoPur to customers in the second quarter of 2017.